NeoGenomics Laboratories vs Tempus AI
Tempus AI reported revenue of $1.3 billion in fiscal 2025, 1.7 times NeoGenomics Laboratories' $727 million in fiscal 2025. NeoGenomics Laboratories' revenue grew 10.1% in its latest year, and Tempus AI's grew 83.4%. NeoGenomics Laboratories had an operating margin of -15.9%, against -19.9% at Tempus AI. Free cash flow was −$22 million at NeoGenomics Laboratories and −$239 million at Tempus AI.
Side by side
| NeoGenomics Laboratories | Tempus AI | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $727M | $1.3B |
| Revenue growth | 10.1% | 83.4% |
| Revenue growth a year, last 5 years | 10.4% | — |
| Gross margin | 43.2% | — |
| Operating margin | −15.9% | −19.9% |
| Net margin | −14.8% | −19.3% |
| Free cash flow | −$22M | −$239M |
| Free cash flow margin | −3.0% | −18.8% |
| Return on capital | −8.8% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $3M |
| Change in diluted share count | 1.1% | 45.4% |
| Last close | $16.84 | $76.05 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $967,816 | sold $208.4 million |
| Piotroski F-score | 5 of 9 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
NeoGenomics LaboratoriesTempus AI
Operating margin
Percent of revenue
NeoGenomics LaboratoriesTempus AI
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NeoGenomics LaboratoriesTempus AI
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the NeoGenomics Laboratories and Tempus AI pages.